You are currently browsing the archives for 17 January 2018.
Displaying 1 - 2 of 2 entries.

BioTrends Analysis Group releases Wave A single LaunchTrends: EXTAVIA report BioTrends Study Group drug.

BioTrends Analysis Group releases Wave A single LaunchTrends: EXTAVIA report BioTrends Study Group, Inc. The survey was finished by U.S drug . Neurologists Extavia . Knowing of Extavia is great but familiarity is more average relatively. Over one-third of current Extavia users show this newest agent is a likely alternative to Betaseron manufactured by Bayer, that was the initial disease modifying agent accepted nearly twenty years ago. Regardless of the relatively high knowing of Extavia, the projected uptake of Extavia is apparently modest with about 50 percent of the Neurologists looking to prescribe Extavia next half a year. The primary advantages clinicians perceive with Extavia may be the every other day time dosing program and similarity to additional interferon brokers.

The latest lawsuit.

We are pleased to see that other pharmacy organizations are as concerned as we are about the individuals who’ll ultimately be denied access to their medications, stated Jon Roth, CEO of the CPhA. We have attempted to work with the State for several years to bring long term solutions to these problems without disrupting the supplier network, but DHCS offers stayed the program toward implementing these devastating cuts on January 9, 2014. Unfortunately it would appear that the only thing DHCS responds to these days is a lawsuit.